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Abstract: Topical application of nerve growth factor (NGF) and adrenergic receptor 
  pharmaceutics are currently in use for corneal ulcers and glaucoma. A recent interest in the 
neuroprotective abilities of NGF has led to a renewed interest in NGF as a therapeutic for 
retinal and choroidal diseases. NGF can promote cell proliferation through actions of the TrkA 
receptor or promote apoptosis through receptor p75NTR. This understanding has led to novel 
interest in the role of NGF for diseases of the posterior eye. The role of β-adrenergic receptor 
agonists and antagonists for treatments of glaucoma, diabetic retinopathy, and their potential 
mechanisms of action, are still under investigation. This review discusses the current knowledge 
and   applications of topical NGF and adrenergic receptor drugs for ocular disease.




Nerve growth factor (NGF) was the first discovered member of a family of factors noted 
to prevent neuronal death called the neurotrophins.1 Levi-Montalcini found that NGF 
was produced in significant levels in mouse salivary glands, and it could prevent apop-
tosis of neurons in culture.2 NGF and one of its receptors, TrkA, are predominantly 
found on sympathetic neurons.3 During development, NGF is the factor that regulates 
neuronal remodeling to establish the precise connections of neuron to target. The target 
produces NGF that is taken up by the nerve terminal and transported retrogradely to 
the cell body. The neuron becomes anti-apoptotic after NGF has reached the cell body.4 
In the establishment of target-neuron connections, sensory and sympathetic nerves 
often will compete for available NGF.5
NGF actions are mediated by two receptors, p75NTR and neurotrophic tyrosine kinase 
receptor type 1 (TrkA). NGF is produced as a proneurotrophin (pro-NGF), which 
preferentially binds to p75NTR. Activation of p75NTR can activate three major signaling 
pathways, including NFκB, c-Jun, and RhoA.6 p75NTR is a low-affinity receptor for 
NGF and is a member of the tumor necrosis factor superfamily. Due to the activation 
of the c-Jun and RhoA, NGF binding to p75NTR is considered to be a predominantly 
pro-apoptotic event. In contrast to the binding of NGF to p75NTR, NGF binds to TrkA 
with high affinity. Phosphorylation of tyrosine residues on TrkA creates binding sites 
for a variety of proteins. The major pathways activated by Trk receptors are Ras, Rac, 





cell migration through PI3K signaling.8 Activation of Ras and 
downstream effectors promotes choroidal cell proliferation.8 
In addition, work on CD34+ cells has demonstrated that NGF 
treatment will increase both migration and tube formation 
(key factors needed for wound healing) via   phosphorylation 
of TrkA and activation of PI3K and Ras (Jadhao et al 
  unpublished results). Thus, increased NGF binding to TrkA 
will promote a neuroprotective effect and should promote 
effective wound healing.
Sympathetic neurotransmitters
While NGF is required for the health of sympathetic 
neurons, norepinephrine signaling may also play a role 
in   neuroprotection and wound healing. Norepinephrine 
signals through activation of either β-adrenergic receptors 
or α-adrenergic receptors. Within the eye, the   presence 
of norepinephrine and noradrenergic receptors has been 
noted around the blood vessels of the choroid and iris.9 
More recently, work has shown that β2-adrenergic 
  receptors are present in the corneal endothelial cells.10,11 
The   presence and role of adrenergic receptors in the 
retina is a bit more   controversial. Laties and Jacobowitz 
did not observe   sympathetic innervation in the retina by 
  immunohistochemical analysis.12 However, Furukawa, using 
immunohistochemical methods as well as transmission and 
scanning electron microscopy, demonstrated that the retina 
receives sympathetic innervation.13 Since then, others have 
demonstrated the presence of dopamine-β-hydroxylase, the 
enzyme that converts dopamine to norepinephrine, in specific 
layers of the retina.14,15 Activation of β-adrenergic receptors 
in the retina stimulates the accumulation of cyclic adenosine 
monophosphate (cAMP).16 We have shown that surgical 
removal of the superior cervical ganglion, which eliminates 
sympathetic neurotransmission to all cranial targets, produces 
increased basement membrane thickening and pericyte loss 
in the retinal vasculature and leads to the activation of Müller 
cells (glial cells of the retina).17,18
The functional role of α-adrenergic receptors and 
β-adrenergic receptors in the eye are target-specific. 
Within the choroid and iris, α-adrenergic receptors mediate 
vasoconstriction, while β-adrenergic receptor stimulation 
produces vasodilation of the vasculature.19,20 A key role 
for both α-adrenergic receptor and β-adrenergic receptor 
  pharmacology in the eye is in the management of glaucoma. 
For the management of glaucoma, agents can be used to either 
decrease the production of aqueous humor (β-adrenergic 
receptor antagonists or α-adrenergic receptor agonists) or 
increase outflow of aqueous humor (prostaglandins).21–23 
The functional role for adrenergic receptor signaling in the 
retina is not clear.
The signaling of adrenergic receptors has been known 
for several decades. Stimulation of β-adrenergic   receptors 
by norepinephrine induces an increase in cAMP levels and 
  phosphorylation of protein kinase A (PKA). PKA is then able to 
transduce into the nucleus of the cell to bind cAMP-  responsive 
element binding (CREB) complexes to induce transcription 
of a number of proteins. In contrast to β-adrenergic receptors, 
which signal predominantly through G-protein   stimulatory 
(Gs), α-adrenergic receptors activate Gq,   producing an 
increase in phospholipase C and calcium   signaling. The ability 
of adrenergic receptors to regulate   aqueous humor production 
and blood flow in the eye is directly related to which receptor 
subtype is   activated. Based on the increased understanding of 
adrenergic   receptor   signaling, a large number of pharmaceutics 
have been   developed for the eye. Fortunately, the eye allows 
for topical delivery, which eliminates problems associated with 
systemic effects of adrenergic receptors on the vasculature of 
other critical organs (heart, lungs).
Based on our understanding of the cellular   localization, 
functions, and signaling of both NGF and the   neurotransmitters 
of the sympathetic nervous system, pharmaceutical 
  companies have developed topical delivery methods for 
both NGF and adrenergic receptor agents for a number of 
disabling ocular disorders.
Cornea
The highest interest in topical NGF therapy is for corneal 
disorders. A number of studies have been done in both 
humans and in animal models to investigate the ability of 
topical NGF to accelerate the healing process in cornea 
ulcers. Investigations in dogs demonstrated that NGF and 
TrkA are present in normal dogs tears, corneal epithelium, 
and the lacrimal gland.24 In dogs, topical treatment with NGF 
did not modulate corneal healing rates.24 In contrast to the 
work in dogs, Esquenazi et al (2005) found that topical NGF 
to rabbits in combination with docosahexenoic acid (DHA) 
after photorefractive keratectomy (PRK) was   associated with 
increased corneal epithelial cell proliferation and increased 
corneal surface area, in contrast to no treatment, NGF 
  treatment alone, or DHA treatment alone.25
While topical NGF has been met with some obstacles 
for corneal healing in animal models of ocular disease, 
work on humans with corneal disorders has provided much 
more promising results. Lambiase et al (2007) reported that 
corneal ulcers produced from a variety of insults (diabetes 
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to traditional therapies for neurotrophic ketatopathy, were 
treated with topical murine NGF (200 ug/ml) for two hours 
for the first two days, followed by one drop six times daily 
until the ulcer healed.26 Remarkable results were obtained in 
these patients; all patients has resolution of the corneal ulcer 
after 26 ± 11 days of NGF treatment. Limited side effects 
were observed and only two patients had a relapse of the 
ulcer during follow-up, which occurred over 72 months.26 
In a recent review by Aloe et al (2008), data on over 200 
patients treated with topical NGF was presented which clearly 
demonstrates that NGF treatment promotes an accelerated 
healing action in the cornea without side effects.27
The role of sympathetic nerves and neurotransmis-
sion has also been investigated for their ability to resolve 
corneal ulcers. Work in rats undergoing surgical superior 
cervical ganglionectomy revealed that ocular sympathetic 
nerves stimulate corneal epithelial cell proliferation under 
both normal conditions and during times of corneal wound-
ing. This increase in proliferation appears to be related to 
release of norepinephrine.28 Since work in animal models 
suggested that adrenergic receptor agents may promote 
corneal wound healing and the cornea possesses an abun-
dance of β-adrenergic receptors in both the epithelium and 
endothelium of the cornea,29 work had been done to evaluate 
the ability of β2-adrenergic receptor antagonism to regulate 
corneal wound healing. In fact, β2-adrenergic receptor 
antagonism increased corneal wound healing by 16%.11,30 
While the mechanism is not clear since norepinephrine is 
suggested to increase epithelial cell proliferation in animals, 
work in humans suggests that a blockade of β2-adrenergic 
receptors in the cornea with topical agents may provide a 
novel therapeutic option for corneal ulcers.
Glaucoma/aqueous humor  
production/outflow
Glaucoma remains one of the most common and   damaging 
ocular diseases. The pharmacological management of 
  glaucoma has increased immensely in the last several decades, 
improved by the increased understanding of the ocular hemo/
aqueous humor dynamics. NGF has been reported to reduce 
retinal ganglion cell loss, which, left unchecked, will lead to 
loss of retinal functions. Elevated intraocular pressure (as 
occurs in glaucoma) in rats produced a significant loss of NGF, 
which was correctable through topical NGF treatment.31 To 
induce glaucoma in a rat model, hypertonic saline is injected 
into the eye, raising intraocular pressure (IOP) to 35 mmHg 
as compared to 24 mmHg in the untreated eye.32 In the rat 
model of glaucoma, topical NGF (200 ug/ml) applied four 
times daily for seven weeks prevented retinal ganglion cell 
death likely through an increase in the Bcl-2/Bax ratio.32 In 
the same study, three human patients with severe glaucoma 
were treated with topical NGF for three months. NGF treat-
ment improved the functional responsiveness of the retina, as 
measured by PERG P50 and VER P100 values, with better 
neural conduction. These positive responses were maintained 
for an additional three months with no treatment. This positive 
response to NGF treatment likely occurs as TrkA phosphoryla-
tion increases Bcl-2 levels, a key anti-apoptotic protein.
The standard of care for many glaucoma patients are 
adrenergic receptor agents. This has occurred since work in 
monkeys demonstrated with timolol (a typical nonselective 
β-adrenergic receptor antagonist) reduced aqueous humor 
levels by 50%.33 These results suggest that antagonism of 
β-adrenergic receptors reduced aqueous humor levels, pro-
ducing a decrease in intraocular pressure. α-adrenergic recep-
tor agents act in much the same way as β-adrenergic receptor 
antagonists to reduce aqueous humor levels in the eye.
Choroid
Little work has been done on topical NGF in the choroid. We 
have previously demonstrated that NGF treatment of human 
choroidal endothelial cells in culture promoted cell prolifera-
tion and migration through the PI3K and ERK1/2 pathway.8
In contrast to the limited information on NGF in the 
  choroid, much work has been done on adrenergic   receptor 
agents in the choroid, likely due to the predominant   vasculature 
of the ciliary arteries of the choroid. We have demonstrated 
that stimulation of α-adrenergic receptor agonists on the vortex 
vein region of the choroid produced vasoconstriction.20 Work 
in the rabbit has shown that neither betaxolol nor timolol had a 
significant effect on choroidal pressure-flow relationships, but 
that both do reach the   systemic   circulation.34 Work on the pos-
terior ciliary microarteries (many of them flowing through the 
choroid) demonstrated that these   particular   vessels do not have 
appreciable β-adrenergic receptor activity. However,   betaxolol 
and propranolol likely produce   vasorelaxation through block-
ade of Ca2+ channels, rather than true β-adrenergic receptor 
activities.35 These results suggest that adrenergic receptor 
agents, particularly β-adrenergic receptor antagonists, may 
be used to influence choroidal blood flow.
Retina
Much of the work on NGF in the retina is focused on its 
potential to protect retinal ganglion cells and the optic nerve 
head in diseases, such as diabetes, carotid artery   occlusion, 





(200 ug/ml) prevented cell death of retinal ganglion cells 
induced by hypertension or ischemia in rats.36 NGF may 
reach the retina as a topical treatment since the final pro-
tein product NGF is only approximately 13–15 kD. This 
size of protein may be naturally transported into the retina 
with ocular fluids. However, the exact mechanism of NGF 
movement into the retina has not been investigated. Using 
the type I diabetic rat model, Ali et al (2008) demonstrated 
that peroxynitrite produced retinal degeneration through 
inhibition of NGF prosurvival activities.37 The increased 
glucose in diabetes produces free radical and peroxynitrite in 
the retina. These authors found that increased peroxynitrite 
led to nitration of the TrkA receptor and enhanced p75NTR 
expression, producing increased apoptosis.37 Similarly, work 
on a carotid artery occlusion model in rats demonstrated that 
an intravitreal injection of NGF protected retinal ganglion 
cells through modulation of the Bax/Bcl-2 ratio to promote 
the prosurvival actions of NGF.38 While NGF does promote 
neuronal survival, some negative effects have also been 
reported. Using the oxygen-induced retinopathy model of 
proliferative diabetic retinopathy, Liu et al (2010) found that 
NGF promoted retinal neovascularization, which was medi-
ated through activities of the TrkA receptor.39 Since retinal 
neovascularization is a negative consequence in most cases, 
NGF actions in this setting are not positive. Nonetheless, 
work has increased on the role of NGF to prevent retinal 
neuronal apoptosis. Since this is likely dependent on which 
NGF receptor is activated (TrkA over p75NTR), additional 
work is needed. All current work on NGF actions in the 
retina have been done following intraocular injections. The 
ability of NGF to reach the retina as a topical treatment is 
still under investigation.
The role of topical adrenergic receptor agents in the 
retina has been previously focused on blood flow regulation. 
Work in humans has demonstrated that epinephrine treat-
ment increased macular blood flow by 8%.40 Work using 
different classes of β-adrenergic receptor antagonists showed 
that all classes increased blood velocities in retinal and 
epiretinal capillaries of healthy human volunteers.41 While 
β-adrenergic receptor antagonists increase retinal blood flow, 
work has also suggested that this may be due primarily to the 
reduction in intraocular pressure and Ca2+ channel actions, 
rather than a direct action on the β-adrenergic receptors.42
The role of β-adrenergic receptors in the regulation of 
  glaucoma is not clear. One of the mechanisms of action 
for betaxolol, one of the most potent β-adrenergic   receptor 
  antagonists for glaucoma, is its ability to alter calcium levels.43,44 
In a recent review, Osborne reported that the   beneficial effects 
of β-adrenergic receptor blockers in glaucoma therapy do not 
appear to involve their actions on β-adrenergic receptors.45 
These findings suggest that the role of β-adrenergic receptor 
antagonists as neuroprotective drugs for glaucoma therapy 
may be related to non-β-adrenergic receptor actions of these 
agents. In diabetic retinopathy, two studies have shown that 
β-adrenergic receptor   antagonists do not reduce diabetic 
retinopathy, in spite of reduced systemic blood pressure.46,47 
Therefore, previous work on β-adrenergic receptor antago-
nists in the retina suggests that they do not   prevent diabetic 
retinopathy in rodents. Nonetheless, the downstream effects of 
β-adrenergic receptor blockade mediated by receptor signal-
ing in the retina are not known. Work in our lab has recently 
reported that blockade of β-adrenergic receptor signaling in 
the normal retina is detrimental, as   evidenced by the reduced 
b-wave amplitude of the electroretinogram (ERG). This agrees 
with previous work in our lab, which showed positive effects 
on the retina following application of β-adrenergic receptor 
agonists in reducing inflammatory marker levels.48–51 While we 
have data that systemic application of β-adrenergic receptor 
antagonists produce retinal dysfunction, we have also recently 
found that β-adrenergic receptor agonists are beneficial to the 
retina. Using the type I diabetic rat model, we demonstrated 
that topical isoproterenol (50 mM given once daily) inhibited 
the functional, biochemical, and histological manifestations 
of diabetic retinopathy. Isoproterenol inhibited the formation 
of degenerate capillaries, prevented apoptosis of cells in the 
ganglion cell layer, and decreased tumor necrosis factor (TNF)
α levels over the 8-month study (Jiang et al in press).
Conclusions
Topical delivery of NGF and adrenergic receptor 
agents has provided physicians with new options for 
  pharmacological management of glaucoma and corneal 
ulcers. Work is ongoing for the role of topical NGF or 
adrenergic   receptor agents for the posterior eye, includ-
ing the choroid and retina. Recent work is investigating a 
potential role for NGF in therapies for diabetic retinopa-
thy through direct actions or through actions using stem 
cells for prevention of retinal ischemia (CD34+ positive 
cells). Topical adrenergic receptor   therapies for the retina 
in diabetic retinopathy are ongoing, as well as   increasing 
the understanding of the mechanisms of β-adrenergic 
receptor antagonist effectiveness in   ganglion cell health 
in glaucoma. Hopefully in the future, work on   topical 
NGF and adrenergic receptor agents in the retina can be 
translated to human patients as easily as it has for corneal 
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